PLRX PLIANT THERAPEUTICS, INC.

NEUTRAL Impact: 4/10 EFFECT
Horizon weeks Filed Apr 7, 2026 Processed 2mo ago SEC 9999999995-26-001103
IPO/offering going effective
Latest settled — T+20d
PLRX ▼ -9.16% at T+20d
NEUTRAL call ✗ call lost -9.16% · α vs SPY -18.94% · entry $1.31 → $1.19
Next anchor: T+60d in 22d
Last close $1.15 (close Jun 8) · -12.21% from $1.31 entry
Entry anchored
Apr 6, 03:59 PM ET
via Databento tick
T+1d
+3.82%
call +3.82% · α +1.28%
$1.36
settled 2mo ago
T+5d
-0.76%
call -0.76% · α -6.09%
$1.30
settled 8w ago
T+20d
-9.16%
call -9.16% · α -18.94%
$1.19
settled 5w ago
T+60d
call — · α —
in 22d

Price Chart

Loading chart...

Executive Summary

Pliant Therapeutics' $300 million shelf registration, including a $50 million at-the-market (ATM) offering program, has become effective. The company can now sell securities from time to time over the next three years, creating potential for future dilution.

Actionable Insight

Monitor for future prospectus supplements or 8-K filings indicating an actual drawdown under the shelf or ATM program, which could lead to near-term stock dilution. The $81M market cap makes even modest issuances potentially impactful.

Key Facts

  • Shelf registration (Form S-3) has become effective, allowing Pliant Therapeutics to raise up to $300 million in capital over the next three years.
  • Of the $300 million, $50 million is designated for an at-the-market (ATM) offering program with Leerink Partners LLC.
  • Securities offered may include common stock, preferred stock, debt, units, and warrants, with specific terms disclosed in future prospectus supplements.
  • The effectiveness allows the company to access capital markets opportunistically, but no immediate offering has been announced.

Financial Impact

Up to $300,000,000 in potential future dilution, with $50,000,000 available immediately under the ATM program

dilutionequity

Risk Factors

  • Future equity issuances could dilute existing shareholders
  • ATM program may be used during periods of low stock price, exacerbating downside pressure

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001103
Document: 9999999995-26-001103-index.html9999999995-26-001103
Document: 9999999995-26-001103.txt9999999995-26-001103
6 reports for PLRX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PLRX — sortable, filterable
Type Now
May 11, 2026
29d ago
8-K
NEUTRAL ★ 4/10
$1.18 $1.18· 0.00%▼ −0.08%$1.15 (−2.54%)
May 11, 2026
29d ago
Press Release
BEARISH ★ 6/10
$1.18 $1.18· 0.00%▲ +0.08%$1.15 (+2.54%)
Apr 17, 2026
7w ago
8-K
MIXED ★ 6/10
$1.29 $1.21▼ −6.20%▼ −7.11%$1.15 (−10.85%)
Apr 7, 2026
9w ago
EFFECT
NEUTRAL ★ 4/10
$1.31 $1.30▼ −0.76%▼ −6.09%$1.15 (−12.21%)
Mar 11, 2026
12w ago
8-K
BULLISH ★ 7/10
$1.41 $1.33▼ −5.67%▼ −4.70%$1.15 (−18.44%)
Mar 3, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$1.29 $1.33▲ +3.10%▲ +4.43%$1.15 (−10.85%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 7h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access